Management of Barrett's esophagus

Simple item page
dc.contributor.authorRahman, A.
dc.contributor.authorSingh, R.
dc.contributor.authorSharma, P.
dc.date.issued2013
dc.description.abstractBoth the incidence of esophageal adenocarcinoma (EA) and its precursor, Barrett’s esophagus (BE) is increasing rapidly in the western world. The progression of BE to EA follows the metaplasia-dysplasia-carcinoma sequence which makes BE the focus of intervention before the development of EA. Considerations are given on the feasibility of a screening program for the population at risk, followed by surveillance of patients found to have BE on endoscopy. Potential management options are then stratified based histological findings of various degrees of dysplasia. This begins with watchful waiting or surveillance as in the case of BE with no dysplasia and low-grade dysplasia (LGD). Ablative therapies such as radiofrequency ablation (RFA) can be considered in non-visible high-grade dysplasia (HGD). With visible lesions and intramucosal cancers, Endoscopic Mucosal Resection (EMR) or Endoscopic Submucosal Dissection (ESD) is generally recommended as a treatment and staging technique. Esophagectomy remains the treatment of choice in EA where there is a high risk of metastasis such as those with deeper submucosal invasion, lymph-vascular or neural invasion and those of higher tumour grade.
dc.description.statementofresponsibilityRahman A. A., Singh R., Sharma P.
dc.identifier.citationMinerva Gastroenterology, 2013; 59(1):13-23
dc.identifier.issn1121-421X
dc.identifier.issn1827-1642
dc.identifier.orcidSingh, R. [0000-0001-9116-6054]
dc.identifier.urihttp://hdl.handle.net/2440/80200
dc.language.isoen
dc.publisherEdizioni Minerva Medica
dc.rightsCopyright status unknown
dc.subjectHumans
dc.subjectBarrett Esophagus
dc.subjectAlgorithms
dc.titleManagement of Barrett's esophagus
dc.typeJournal article
pubs.publication-statusPublished

Files

Collections

Medicine publications